Company Overview of Dr. Reddy's Laboratories Ltd.
Dr. Reddy’s Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment produces and markets finished pharmaceutical products as branded formulations or generic finished dosages. This segment also engages in biologics business. The PSAI segment develops active pharmaceutical ingredients (APIs) and intermediaries, which are used as principal ingredients for finished pharmaceutical products. This segment also offers contract research services to other companies; and manufactures and sells APIs and steroids in accordanc...
8-2-337, Road No. 3
Founded in 1984
Key Executives for Dr. Reddy's Laboratories Ltd.
Co-Chairman, Chief Executive Officer, Managing Director, Member of the Management Council, Member of Management Committee, Member of Stakeholders' Relationship Committee, Member of Investment Committee and Member of Corporate Social Responsibility Committee
Total Annual Compensation: $6.3M
Chairman of The Board, Member of The Management Council, Chairman of Management Committee, Member of Stakeholders' Relationship Committee, Member of Investment Committee and Member of Corporate Social Responsibility Committee
Total Annual Compensation: $6.3M
Compensation as of Fiscal Year 2015.
Dr. Reddy's Laboratories Ltd. Key Developments
Drug makers Reportedly Seeks Acquisition Of Products To Be Hived Off Teva Pharmaceutical
Nov 19 15
Drug makers reportedly are seeking acquisition of tens of products to be hived off in the US by Teva Pharmaceutical Industries Limited (NYSE:TEVA). Cipla Limited (NSEI:CIPLA) and Glenmark Pharmaceuticals Ltd. (BSE:532296) are among some 30 companies bidding for tens of products to be hived off in the US, the world's biggest pharma market, as part of Teva Pharmaceutical Industries's acquisition of Allergan plc (NYSE:AGN)'s generics business. Industry sources indicated to ET that Indian drug makers will be keen to buy the generic portfolio on offer, which could be valued at a minimum of $500 million. By regulations of the US Federal Trade Commission, Teva Pharmaceutical Industries needs to undergo a divestiture process for the overlapping products as part of its deal to ensure fair market competition. "In the second round about 20 companies are expected to figure and the actual valuations of the bids will be known during that process," one industry source said. While it could not be confirmed immediately, Cadila Healthcare Limited (BSE:532321) and Dr. Reddy's Laboratories Ltd. (BSE:500124)'s may also form part of the list that made it to the second round. In response to questions from ET, a Cipla spokesperson said the company does not comment on any product or partner discussions. "As a pharmaceutical company we are constantly in discussions with multiple parties on potential collaboration opportunities - in line with our aspiration to drive access and ensure availability of high quality, affordable medicines," the person said. Glenmark too declined to comments.
Dr. Reddy's Laboratories Ltd. - Special Call
Nov 6 15
To clarify investors’ queries on the warning letter issued by the US FDA dated November 05, 2015
Biocodex Signs Distribution Agreement with Dr. Reddy’s to Market Products in Romania
Nov 4 15
Dr. Reddy's Laboratories has entered into a strategic alliance with Biocodex to market and distribute Biocodex products in the Romanian market. Biocodex has announced the change in partnership and effective October 01, 2015, Dr. Reddy's has been given the complete rights for promotion and distribution of the Biocodex products across Romania.
Similar Private Companies By Industry
Recent Private Companies Transactions
Most Searched Private Companies
Sponsored Financial Commentaries